Literature DB >> 32810026

Estimating the Direct Medical Outpatient Costs of Diagnosis and Treatment of Trichomoniasis Among Commercially Insured Patients in the United States, 2016 to 2018.

Sagar Kumar, Harrell Chesson1, Thomas L Gift1.   

Abstract

ABSTRACT: We used 2016-2018 outpatient claims data to calculate direct outpatient medical costs per case of trichomoniasis in 2019 US dollars. The outpatient, drug, and total costs per treated case of trichomoniasis were $174, $39, and $213, respectively. Total costs were higher for female patients ($220) than for male patients ($158).
Copyright © 2020 American Sexually Transmitted Diseases Association. All rights reserved.

Entities:  

Mesh：

Year:  2021        PMID： 32810026      PMCID： PMC9425440          DOI： 10.1097/OLQ.0000000000001266

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN： 0148-5717            Impact factor:   3.868


  12 in total

1.  Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial.

Authors:  D B Rein; W J Kassler; K L Irwin; L Rabiee
Journal:  Obstet Gynecol       Date:  2000-03       Impact factor: 7.661

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

3.  Prevalence of Trichomonas vaginalis Among Civilian, Noninstitutionalized Male and Female Population Aged 14 to 59 Years: United States, 2013 to 2016.

Authors:  Elaine W Flagg; Elissa Meites; Christi Phillips; John Papp; Elizabeth A Torrone
Journal:  Sex Transm Dis       Date:  2019-10       Impact factor: 2.830

4.  Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.

Authors:  Jie Zhang; Fenglong Xie; Elizabeth Delzell; Lang Chen; Kevin L Winthrop; James D Lewis; Kenneth G Saag; John W Baddley; Jeffrey R Curtis
Journal:  JAMA       Date:  2012-07-04       Impact factor: 56.272

5.  Utilization and cost of diagnostic methods for sexually transmitted infection screening among insured American youth, 2008.

Authors:  Kwame Owusu-Edusei; Hang T Nguyen; Thomas L Gift
Journal:  Sex Transm Dis       Date:  2013-05       Impact factor: 2.830

6.  Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women.

Authors:  Melinda B Nye; Jane R Schwebke; Barbara A Body
Journal:  Am J Obstet Gynecol       Date:  2009-02       Impact factor: 8.661

7.  The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008.

Authors:  Kwame Owusu-Edusei; Harrell W Chesson; Thomas L Gift; Guoyu Tao; Reena Mahajan; Marie Cheryl Bañez Ocfemia; Charlotte K Kent
Journal:  Sex Transm Dis       Date:  2013-03       Impact factor: 2.830

8.  Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005.

Authors:  Kwame Owusu-Edusei; Mehul N Tejani; Thomas L Gift; Charlotte K Kent; Guoyu Tao
Journal:  Sex Transm Dis       Date:  2009-06       Impact factor: 2.830

9.  Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women.

Authors:  Jane R Schwebke; C A Gaydos; T Davis; J Marrazzo; D Furgerson; S N Taylor; B Smith; L H Bachmann; R Ackerman; T Spurrell; D Ferris; C A Burnham; H Reno; J Lebed; D Eisenberg; P Kerndt; S Philip; J Jordan; N Quigley
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

10.  Testing for Sexually Transmitted Diseases in US Public Health Laboratories, 2016.

Authors:  Alissa Davis; Anne Gaynor
Journal:  Sex Transm Dis       Date:  2020-02       Impact factor: 2.830
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.